Secondary Logo

Institutional members access full text with Ovid®

Heparin-Free Prolonged Intermittent Hemodialysis Using Calcium-Free Citrate Dialysate in Critically Ill Patients

Faguer, Stanislas MD, PhD1,2,3; Saint-Cricq, Morgane MD1; Nogier, Marie-Béatrice MD1; Labadens, Isabelle PharmD4; Lavayssiere, Laurence MD1; Kamar, Nassim MD, PhD1,2; Cointault, Olivier MD1

doi: 10.1097/CCM.0000000000002694
Clinical Investigations

Objectives: Critically ill patients who have a high risk of bleeding but require prolonged intermittent dialysis need a heparin-free easy-to-use alternative type of anticoagulation within the dialysis circuit. We assessed the safety and efficiency of heparin-free regional citrate anticoagulation of the dialysis circuit using a calcium-free citrate-containing dialysate, with calcium reinjected according to ionic dialysance.

Design: Prospective cohort study.

Setting: Critical care units.

Patients: Critically ill patients who required renal replacement therapy.

Interventions: None.

Measurements and Main Results: A total of 101 dialysis sessions were performed in 35 patients (mechanical ventilation n = 78; norepinephrine n = 13). Median duration of dialysis was 294 minutes (interquartile range, 240–300), and median ultrafiltration volume was 2.3 L (1–2.8). Urea and β2-microglobulin reduction rates were 64.5% ± 0.4% and 48% ± 0.13%, respectively. Postfilter ionized calcium was 0.35 ± 0.17 and 0.38 ± 0.14 mmol/L at 1 and 3 hours, respectively, within the extracorporeal circuit. A major clotting event that led to premature termination of the session occurred in only three of 101 sessions. In these three cases, major catheter dysfunction occurred before clotting within the circuit. Prefilter ionized calcium remained within narrow ranges (before/after change +0.07 ± 0.006 mmol/L), and total-to-ionized calcium ratio, a surrogate marker for citratemia, was unchanged.

Conclusions: Dialysis anticoagulation with calcium-free citrate-containing dialysate and calcium reinjection according to ionic dialysance is an easy-to-use, efficient, and inexpensive form of heparin-free regional anticoagulation. It allows prolonged hemodialysis sessions in critically ill patients without the need to systemically monitor ionized calcium. Furthermore, sessions can be safely extended according to the hemodynamic tolerance to ensure an adequate dose of dialysis and a negative water balance, a major point in patients with severe acute kidney disease.

Supplemental Digital Content is available in the text.

1Département de Néphrologie et Transplantation d’organes, Unité de Réanimation, CHU de Toulouse, Hôpital Rangueil, Toulouse, France.

2Université Toulouse-3, Toulouse, France.

3Institut National de la Santé et de la Recherche Médicale U1048 (équipe 12), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France.

4Pharmacology department, Unité de Pharmacie clinique, CHU de Toulouse, Toulouse, France.

Drs. Faguer, Saint-Cricq, and Cointault designed the study and analyzed the data; Drs. Faguer, Saint-Cricq, Lavayssiere, Nogier, Kamar, and Cointault followed the patients; Mr. Labadens furnished the dialysate and calcium solution. Faguer and Cointault wrote the article.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (

The authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, E-mail:

Copyright © by 2017 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.